ERBB2 and neoplasm: Although patients with MYC/HER2 co-amplified breast tumours have worse outcomes than patients with single gene amplified tumours[49], the predictive value of MYC amplification in the response to adjuvant trastuzumab in HER2-positive breast tumours is still unclear[50].